Impact of Lockdown Restrictions on Treatment of Leprosy: A Retrospective Analysis

Swapna Dominic1, Sarita Sasidharanpillai1, Reshmi Gangan2

  • 1Department of Dermatology and Venereology, Government Medical College, Kozhikode, Kerala, India.

Insights

COVID-19 lockdown measures disrupted leprosy treatment for 20.3% of patients due to transport issues. This highlights the need for continued healthcare access during pandemics.

Area of Science:

  • Medical Research
  • Epidemiology
  • Public Health

Background:

  • The COVID-19 pandemic has significantly impacted global health services.
  • Leprosy treatment requires consistent multi-drug therapy (MDT) for effective management.
  • Lockdown measures implemented to control COVID-19 may have affected chronic disease care.

Purpose of the Study:

  • To evaluate the effect of COVID-19 lockdown measures on the continuity of leprosy treatment.
  • To identify challenges faced by leprosy patients during the pandemic.

Main Methods:

  • A retrospective analysis of leprosy patient records was performed.
  • Data from a tertiary referral center covered the period from March 2020 to May 2021.
  • Patient treatment adherence and reasons for discontinuation were examined.

Main Results:

  • Out of 59 patients on multi-drug therapy (MDT), 12 (20.3%) discontinued treatment due to conveyance difficulties during lockdown.
  • Three patients (5.1%) were lost to follow-up.
  • Two patients (3.4%) contracted COVID-19 while undergoing MDT.

Conclusions:

  • Lockdown measures posed significant challenges to leprosy treatment adherence.
  • Healthcare systems must ensure uninterrupted care for chronic conditions during pandemics.
  • Proactive strategies are needed to mitigate the impact of public health crises on leprosy control programs.
Abstract

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
225
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
297
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
412
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
305